These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1466156)

  • 21. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
    Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR
    Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin.
    Westbury C; Vini L; Fisher C; Harmer C
    Thyroid; 2000 Feb; 10(2):171-6. PubMed ID: 10718555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thyroid carcinoma with biphasic clinical course and evolution in medullary carcinoma-follicular variant. A case report and an immunocytochemical demonstration of calcitonin and thyroglobulin in the same neoplastic cells.
    Baschieri I; Ronga G; Fiorentino A; Mariani P; Carlei F
    J Nucl Med Allied Sci; 1990; 34(2):71-6. PubMed ID: 2246675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thyrotrophin receptors, tumour radioiodine concentration and thyroglobulin secretion in differentiated thyroid cancers.
    Edmonds CJ; Kermode JC
    Br J Cancer; 1985 Oct; 52(4):537-41. PubMed ID: 2998424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
    Lind P; Gallowitsch HJ
    Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients.
    Schlumberger M; Hitzel A; Toubert ME; Corone C; Troalen F; Schlageter MH; Claustrat F; Koscielny S; Taieb D; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Torlontano M; Tenenbaum F; Bardet S; Bussière F; Girard JJ; Morel O; Schneegans O; Schlienger JL; Prost A; So D; Archambeaud F; Ricard M; Benhamou E
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2487-95. PubMed ID: 17426102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radioiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer.
    Küçük ON; Gültekin SS; Aras G; Ibiş E
    Nucl Med Commun; 2006 Mar; 27(3):261-6. PubMed ID: 16479246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Serum thyroglobulin in the diagnosis of metastases of differentiated thyroid cancer. Effect of suppressive thyroid hormone substitution on the diagnostic accuracy of thyroglobulin values].
    Müller-Gärtner HW; Schneider C; Tempel MT
    Nuklearmedizin; 1986 Oct; 25(5):194-200. PubMed ID: 3797259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thyroglobulin may be undetectable in the serum of patients with metastatic disease secondary to differentiated thyroid carcinoma. Follow-up of differentiated thyroid carcinoma.
    Grant S; Luttrell B; Reeve T; Wiseman J; Wilmshurst E; Stiel J; Donohoe D; Cooper R; Bridgman M
    Cancer; 1984 Oct; 54(8):1625-8. PubMed ID: 6478402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
    Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endogenously labeled thyroid hormones (131I-T3/T4) in sera of patients with differentiated thyroid carcinoma.
    Lukinac L; Franceschi M; Nöthig-Hus D; Lechpammer S; Tomasić J; Vranesić B; Pape E; Kusić Z
    Thyroid; 1996 Jun; 6(3):201-6. PubMed ID: 8837327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoclonal antibodies to human thyroglobulin: evaluation of immunoreactivity.
    Narkar AA; Shah DH; Yadav J; Swaroop D; Mulherkar R
    Hybridoma; 1992 Dec; 11(6):803-13. PubMed ID: 1284124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thyroglobulin production by malignant thyroid tumors. An immunocytochemical and radioimmunoassay study.
    Ryff-de Lèche A; Staub JJ; Kohler-Faden R; Müller-Brand J; Heitz PU
    Cancer; 1986 Mar; 57(6):1145-53. PubMed ID: 2417694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thyroglobulin and calcitonin immunoreactivity in canine thyroid carcinomas.
    Moore FM; Kledzik GS; Wolfe HJ; DeLellis RA
    Vet Pathol; 1984 Mar; 21(2):168-73. PubMed ID: 6375099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
    Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
    Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth and function of thirty-four human benign and malignant thyroid xenografts in untreated nude mice.
    Dralle H; Böcker W; Döhler KD; Schröder S; Haindl H; Geerlings H; Schwarzrock R; Pichlmayr R
    Cancer Res; 1985 Mar; 45(3):1239-45. PubMed ID: 3971371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.